# Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults

> **NCT03039790** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 528 (actual)

## Conditions studied

- Healthy Volunteers
- Norovirus

## Interventions

- **BIOLOGICAL:** NoV Vaccine

## Key facts

- **NCT ID:** NCT03039790
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-21
- **Primary completion:** 2021-07-22
- **Final completion:** 2021-07-22
- **Target enrollment:** 528 (ACTUAL)
- **Last updated:** 2022-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03039790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03039790, "Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03039790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*